Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “neutral” rating reiterated by investment analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Friday. They presently have a $17.00 price objective on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price objective points to a potential upside of 12.81% from the stock’s previous close.
A number of other analysts have also recently issued reports on FOLD. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. BidaskClub cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital reiterated a “buy” rating and issued a $16.50 target price (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Finally, Robert W. Baird lifted their target price on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average price target of $18.07.
Amicus Therapeutics (NASDAQ FOLD) opened at 15.06 on Friday. The stock’s market cap is $2.48 billion. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $16.60. The firm’s 50-day moving average is $14.11 and its 200-day moving average is $10.59.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period last year, the company posted ($0.40) earnings per share. On average, analysts forecast that Amicus Therapeutics will post ($1.32) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/10/08/goldman-sachs-group-inc-the-reiterates-neutral-rating-for-amicus-therapeutics-inc-fold.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of Amicus Therapeutics stock in a transaction on Thursday, July 13th. The stock was purchased at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.40% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas lifted its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics in the second quarter worth $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics in the second quarter worth $124,000. Aperio Group LLC lifted its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares during the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of Amicus Therapeutics in the second quarter worth $145,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.